MAY 25, 2020 11:02 PM PDT

Potential Targets for Alcohol Induced Liver Disease

WRITTEN BY: Nouran Amin

Alcohol-related liver disease (ALD) is a fatal condition targeting more than 150 million people. Part of what makes it deadly is the unavailability of treatment besides a transplant. To address these challenges, researchers at Massachusetts General Hospital (MGH) have uncovered key molecular steps involved in ALD that may provide targets for drug therapy development.

Learn more about ALD:

The groundbreaking findings were published in Proceedings of the National Academy of Sciences (PNAS) and describes how researchers achieved their results by combining RNA sequence analysis of patient liver samples with transgenic mouse studies. Researchers were able to identify two promising potential molecular targets for developing ALD therapeutics-- cGAS and Cx32. The senior author is Suraj J. Patel, MD, PhD, a research fellow in the Department of Medicine.

"Now that we know the key players in this pathway, we finally have drug targets for treatment development," says the lead author on the study is Jay Luther, MD, gastroenterologist and Director of the Mass General Alcohol Liver Center. "Until now, we haven't had any successful leads. Meanwhile, the number of patients has grown."

Before the study, scientists already knew that liver cell (hepatocyte) death in ALD is supported IFN regulatory factor (IRF3) which fuels a strong secondary inflammatory response that affects nearby cells eventually leading to liver failure. However, the question they came up with was how does alcohol activate IRF3 and which pathways are amplified that deliver the disease spread throughout the liver.

"Until now, now we had only few clues about why alcohol-related liver disease progresses the way it does, but this research fills in key pieces of the puzzle," says Patel.

"It is very encouraging to see that we now have evidence-based targets for drug development for ALD," says Luther.

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 14, 2022
Drug Discovery & Development
COVID-19 Drug Combo More Effective than Single Drugs
APR 14, 2022
COVID-19 Drug Combo More Effective than Single Drugs
COVID-19 is more effectively treated by a combination of drugs than singular drugs alone. The corresponding study was pu ...
APR 28, 2022
Health & Medicine
Antidepressants Not Associated Improved Quality of Life
APR 28, 2022
Antidepressants Not Associated Improved Quality of Life
According to a recently published study in PLoS, antidepressants do not improve health-related quality of life (HRQoL) o ...
JUN 14, 2022
Cancer
Maintaining Sample Temperature: Q&A From a Corning Scientist
JUN 14, 2022
Maintaining Sample Temperature: Q&A From a Corning Scientist
Generally speaking, bad things can happen when a cell sample temperature gets too hot or too cold. Temperature instabili ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 22, 2022
Cell & Molecular Biology
A New, Innovative Process for Clarifying and Sterile Filtering Cells for Protein Purification Workflows
JUN 22, 2022
A New, Innovative Process for Clarifying and Sterile Filtering Cells for Protein Purification Workflows
Introduction Centrifugation and filtration have been widely accepted as techniques required for clarifying complex cell ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
Loading Comments...